Medizinische Klinik III, Department of Cardiology and Cardiovascular Medicine, University of Tübingen, Otfried-Müller-St 10, 72076 Tübingen, Germany.
Circ Res. 2012 Oct 26;111(10):1297-307. doi: 10.1161/CIRCRESAHA.112.276444. Epub 2012 Aug 27.
The recently discovered chemokine CXC motif ligand 16 (CXCL16) is highly expressed in atherosclerotic lesions and is a potential pathogenic mediator in coronary artery disease.
The aim of this study was to test the role of CXCL16 on platelet activation and vascular adhesion, as well as the underlying mechanism and signaling pathway.
Reverse-transcriptase polymerase chain reaction, Western blotting, confocal microscopy, and flow cytometry revealed that CXCL16-specific receptor, CXC motif receptor 6, is highly expressed in platelets. According to flow cytometry and confocal microscopy, stimulation of platelets with CXCL16 induced platelet degranulation, integrin α(IIb)β(3) activation, and shape change. CXCL16 increased Akt phosphorylation (Thr(308)/Ser(473)), an effect abrogated by phosphatidylinositide 3-kinase inhibitors wortmannin (100 nmol/L) and LY294002 (25 µmol/L). The phosphatidylinositide 3-kinase inhibitors and Akt inhibitor SH-6 (20 µmol/L) further diminished CXCL16-induced platelet activation. CXCL16-mediated platelet degranulation, integrin α(IIb)β(3) activation, and Akt phosphorylation were blunted in platelets lacking CXCL16-specific receptor CXC motif receptor 6. CXCL16-induced platelet activation was abrogated in Akt1- or Akt2-deficient platelets. CXCL16 enhanced platelet adhesion to endothelium in vitro after high arterial shear stress (2000(-s)) and to injured vascular wall in vivo after carotid ligation. CXCL16-induced stimulation of platelet adhesion again was prevented by phosphatidylinositide 3-kinase and Akt inhibitors. Apyrase and antagonists of platelet purinergic receptors P(2)Y(1) (MRS2179, 100 µmol/L) and especially P(2)Y(12) (Cangrelor, 10 µmol/L) blunted CXCL16-triggered platelet activation as well as CXCL16-induced platelet adhesion under high arterial shear stress in vitro and after carotid ligation in vivo.
The inflammatory chemokine CXCL16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling and paracrine activation, suggesting a decisive role for CXCL16 in linking vascular inflammation and thrombo-occlusive diseases.
最近发现的趋化因子 CXC 基序配体 16(CXCL16)在动脉粥样硬化病变中高度表达,是冠状动脉疾病潜在的致病介质。
本研究旨在检测 CXCL16 对血小板激活和血管黏附的作用及其潜在的机制和信号通路。
逆转录聚合酶链反应、Western blot、共聚焦显微镜和流式细胞术显示,CXCL16 的特异性受体 CXC 基序受体 6 在血小板中高度表达。根据流式细胞术和共聚焦显微镜,CXCL16 刺激血小板可诱导血小板脱颗粒、整合素α(IIb)β(3)激活和形态改变。CXCL16 增加 Akt 的磷酸化(Thr(308)/Ser(473)),该作用可被磷脂酰肌醇 3-激酶抑制剂wortmannin(100 nmol/L)和 LY294002(25 μmol/L)所阻断。磷脂酰肌醇 3-激酶抑制剂和 Akt 抑制剂 SH-6(20 μmol/L)进一步减弱了 CXCL16 诱导的血小板激活。在缺乏 CXCL16 特异性受体 CXC 基序受体 6 的血小板中,CXCL16 介导的血小板脱颗粒、整合素α(IIb)β(3)激活和 Akt 磷酸化作用减弱。在 Akt1 或 Akt2 缺陷的血小板中,CXCL16 诱导的血小板激活被阻断。在高动脉剪切力(2000(-s))下,CXCL16 增强血小板在体外与内皮的黏附,在体内经颈总动脉结扎后增强血小板在受损血管壁上的黏附。磷脂酰肌醇 3-激酶和 Akt 抑制剂可防止 CXCL16 诱导的血小板黏附。血小板 purinergic 受体 P(2)Y(1)(MRS2179,100 μmol/L)和 P(2)Y(12)(坎格雷洛,10 μmol/L)的拮抗剂可抑制 CXCL16 触发的血小板激活以及 CXCL16 诱导的血小板在体外高动脉剪切力下和体内颈总动脉结扎后的黏附,从而减弱 CXCL16 诱导的血小板激活。
炎症趋化因子 CXCL16 通过 CXC 基序受体 6 依赖性磷脂酰肌醇 3-激酶/Akt 信号和旁分泌激活触发血小板激活和黏附,提示 CXCL16 在将血管炎症与血栓闭塞性疾病联系起来方面具有决定性作用。